BioMed Central | Members | Novartis Group

Submit a manuscript Register Contact us

Institution search

Search by institution name/city

Members

Australia (21)
Austria (6)
Belgium (3)
Brazil (3)
Burkina Faso (1)
Canada (27)
Central African Republic (1)
China (3)
Cyprus (3)
Czech Republic (1)
Denmark (1)
Ethiopia (1)
Finland (6)
France (7)
Germany (51)
Ghana (3)
Greece (1)
Hong Kong (2)
Hungary (1)
India (7)
Ireland (1)
Israel (1)
Italy (14)
Kenya (3)
Korea, South (2)
Lebanon (1)
Lithuania (1)
Luxembourg (1)
Madagascar (1)
Malaysia (3)
Mexico (1)
Morocco (2)
Netherlands (10)
New Zealand (1)
Nigeria (2)
Norway (4)
Poland (2)
Portugal (1)
Romania (1)
South Africa (6)
Spain (14)
Sweden (9)
Switzerland (10)
Taiwan (3)
Tanzania (2)
Thailand (1)
Trinidad and Tobago (1)
Turkey (1)
Uganda (1)
United Kingdom (49)
United States of America (157)

Advertisement

Member - Novartis Group

Novartis is a world leader in the research and development of products to protect and improve health and well-being.

http://www.novartis.com/

Research staff and students at Novartis Group:

Do you realize that you can now publish in journals published by BioMed Central without directly paying any article-processing charges? Payment of your article-processing charges is covered by Novartis Group's Prepay Membership. Read more information about publishing your articles with us.

Work published with BioMed Central, Chemistry Central and SpringerOpen by researchers at Novartis Group

Display/download options Articles per page: 25 | 50 | 100

Display options

Editor's summary Citation

Download options

Send
To

	1.	Software JSME: a free molecule editor in JavaScript Bruno Bienfait, Peter Ertl Journal of Cheminformatics 2013, 5:24 (21 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary \| Graphical abstract A free molecule editor written in JavaScript was developed and is released under the terms of permissive BSD license. The editor is compatible with JME, has practically the same user interface as well as the web application programming interface.
	2.	Commentary *Fulani show decreased susceptibility to Plasmodium falciparum* infection versus Mossi: data from a community-wide screening and treatment of asymptomatic carriers in Burkina Faso** Alfred B Tiono, Sodiomon B Sirima, Kamal Hamed Malaria Journal 2013, 12:163 (16 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary This study confirmed that, in the same environment, individuals belonging to the Fulani ethnic group have a lower susceptibility to Plasmodium falciparum infection than Mossi individuals.
	3.	Research Potential of patient-reported outcomes as nonprimary endpoints in clinical trials Ari Gnanasakthy, Sandra Lewis, Marci Clark, Margaret Mordin, Carla DeMuro Health and Quality of Life Outcomes 2013, 11:83 (15 May 2013) Abstract \| Provisional PDF \| PubMed
	4.	Poster presentation Reduction in oral corticosteroid use in patients with severe allergic (IgE-mediated) asthma receiving omalizumab in a real-world setting Gert-Jan Braunstahl, Jan Chlumsky, Guy Peachey, Robert Maykut, Chien-Wei Chen Clinical and Translational Allergy 2013, 3(Suppl 1):P13 (3 May 2013) Full text \| PDF
	5.	Oral presentation Omalizumab in the treatment of severe allergic (IgE-mediated) asthma: an update on recent developments Marc Humbert, Janice Canvin, Tamara Kiechle, Phil Lowe, Veit Erpenbeck Clinical and Translational Allergy 2013, 3(Suppl 1):O12 (3 May 2013) Full text \| PDF
	6.	Poster presentation Healthcare utilization and indirect cost of treatment associated with severe allergic asthma in a real-world setting Gert-Jan Braunstahl, Marco Deenstra, Janice Canvin, Guy Peachey, Chien-Wei Chen, Panayiotis Georgiou, Robert Maykut Clinical and Translational Allergy 2013, 3(Suppl 1):P1 (3 May 2013) Full text \| PDF
	7.	Research article Robenacoxib versus meloxicam for the management of pain and inflammation associated with soft tissue surgery in dogs: a randomized, non-inferiority clinical trial Philippe Gruet, Wolfgang Seewald, Jonathan N King BMC Veterinary Research 2013, 9:92 (2 May 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary A treatment regimen of a new NSAID, robenacoxib, by subcutaneous injection followed by oral tablets, demonstrates good tolerability and non inferior efficacy compared to meloxicam for the management of perioperative pain and inflammation associated with soft tissue surgery in dogs.
	8.	Research article Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study Shannon Allen Ferrante, Jagpreet Chhatwal, Clifford A Brass, Antoine C El Khoury, Fred Poordad, Jean-Pierre Bronowicki, Elamin H Elbasha BMC Infectious Diseases 2013, 13:190 (27 April 2013) Abstract \| Full text \| PDF \| PubMed
	9.	Research article Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-analysis of randomized placebo-controlled trials Jiangna Han, Lu Dai, Nanshan Zhong BMC Pulmonary Medicine 2013, 13:26 (25 April 2013) Abstract \| Full text \| PDF \| PubMed
	10.	Meeting abstract Asthma diagnosis and treatment – 1015. Improvements in lung function in an indian population with IgE mediated asthma receiving omalizumab in a real-world setting Randeep Guleria, Deepak Talwar, Ashok Mahashur, Mangala Kotnis World Allergy Organization Journal 2013, 6(Suppl 1):P15 (23 April 2013) Full text \| PDF
	11.	Research Artemisinin-based combination therapy availability and use in the private sector of five AMFm phase 1 countries Ben Davis, Joel Ladner, Kelley Sams, Ebru Tekinturhan, Donald de Korte, Joseph Saba Malaria Journal 2013, 12:135 (22 April 2013) Abstract \| Full text \| PDF \| PubMed \| Editor’s summary The objective of this study was to assess anti-malarial stock and purchase patterns at private outlets in five Phase 1 countries in the Affordable Medicines Facility-malaria programme, in regard to three of the core AMFm goals: increase the affordability of quality-assured artemisinin combination therapy, increase the availability of ACT, and crowd out artemisinin monotherapies and other substandard therapies.
	12.	Research *Proteolysis of Xenopus* Cip-type CDK inhibitor, p16^Xic2, is regulated by PCNA binding and CDK2 phosphorylation** Xi-Ning Zhu, Dong Hyun Kim, Horng-Ru Lin, Varija N Budhavarapu, Herbert B Rosenbaum, Paul R Mueller, P Renee Yew Cell Division 2013, 8:5 (22 April 2013) Abstract \| Full text \| PDF \| PubMed
	13.	Research Notch4 is required for tumor onset and perfusion Maria José Costa, Xiaoqing Wu, Henar Cuervo, Ruchika Srinivasan, Seth K Bechis, Ellen Cheang, Olivera Marjanovic, Thomas Gridley, Christin A Cvetic, Rong A Wang Vascular Cell 2013, 5:7 (20 April 2013) Abstract \| Full text \| PDF \| PubMed
	14.	Research article Resource utilization, costs and treatment patterns of switching and discontinuing treatment of MS patients with high relapse activity Karina Raimundo, Haijun Tian, Huanxue Zhou, Xin Zhang, Kristijan H Kahler, Neetu Agashivala, Edward Kim BMC Health Services Research 2013, 13:131 (8 April 2013) Abstract \| Full text \| PDF \| PubMed
	15.	Original investigation Vildagliptin in addition to metformin improves retinal blood flow and erythrocyte deformability in patients with type 2 diabetes mellitus – results from an exploratory study Christine Berndt-Zipfel, Georg Michelson, Markus Dworak, Michael Mitry, Andrea Löffler, Andreas Pfützner, Thomas Forst Cardiovascular Diabetology 2013, 12:59 (8 April 2013) Abstract \| Full text \| PDF \| PubMed
	16.	Research article Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia Andrew M Stein, Giovanni Martinelli, Timothy P Hughes, Martin C Müller, Lan Beppu, Enrico Gottardi, Susan Branford, Simona Soverini, Richard C Woodman, Andreas Hochhaus, Dong-Wook Kim, Giuseppe Saglio, Jerald P Radich BMC Cancer 2013, 13:173 (2 April 2013) Abstract \| Full text \| PDF \| PubMed
	17.	New method A quantitative homogeneous assay for fragile X mental retardation 1 protein Gabi Schutzius, Dorothee Bleckmann, Sandra Kapps-Fouthier, Francesco di Giorgio, Bernd Gerhartz, Andreas Weiss Journal of Neurodevelopmental Disorders 2013, 5:8 (2 April 2013) Abstract \| Full text \| PDF \| PubMed
	18.	Methodology article Differential expression analysis for paired RNA-seq data Lisa M Chung, John P Ferguson, Wei Zheng, Feng Qian, Vincent Bruno, Ruth R Montgomery, Hongyu Zhao BMC Bioinformatics 2013, 14:110 (27 March 2013) Abstract \| Provisional PDF \| PubMed
	19.	Review Experimental designs for small randomised clinical trials: an algorithm for choice Catherine Cornu, Behrouz Kassai, Roland Fisch, Catherine Chiron, Corinne Alberti, Renzo Guerrini, Anna Rosati, Gerard Pons, Harm Tiddens, Sylvie Chabaud, Daan Caudri, Clément Ballot, Polina Kurbatova, Anne-Charlotte Castellan, Agathe Bajard, Patrice Nony, Orphanet Journal of Rare Diseases 2013, 8:48 (25 March 2013) Abstract \| Full text \| PDF \| PubMed
	20.	Research Gamma radiation mediated green synthesis of gold nanoparticles using fermented soybean-garlic aqueous extract and their antimicrobial activity Ahmed Ibrahim El-Batal, Abd-Algawad M Hashem, Noha M Abdelbaky SpringerPlus 2013, 2:129 (23 March 2013) Abstract \| Full text \| PDF
	21.	Research article Improving basic and translational science by accounting for litter-to-litter variation in animal models Stanley E Lazic, Laurent Essioux BMC Neuroscience 2013, 14:37 (22 March 2013) Abstract \| Full text \| PDF \| PubMed
	22.	Oral presentation Reproducibility in cheminformatics and computational chemistry research: certainly we can do better than this Gregory A Landrum Journal of Cheminformatics 2013, 5(Suppl 1):O4 (22 March 2013) Full text \| PDF
	23.	Oral presentation Get your chemistry right with KNIME Thorsten Meinl, Gregory Landrum Journal of Cheminformatics 2013, 5(Suppl 1):F1 (22 March 2013) Full text \| PDF
	24.	Research article Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study Jun Guo, Yiran Huang, Xu Zhang, Fangjian Zhou, Yinghao Sun, Shukui Qin, Zhangqun Ye, Hui Wang, Annette Jappe, Patrick Straub, Nicoletta Pirotta, Sven Gogov BMC Cancer 2013, 13:136 (21 March 2013) Abstract \| Full text \| PDF \| PubMed
	25.	Poster presentation In vitro efficiency of Amikacin Inhale, a novel drug-device delivery system N Kadrichu, S Boc, K Corkery, P Challoner Critical Care 2013, 17(Suppl 2):P81 (19 March 2013) Full text \| PDF